Navigation Links
Lightlake Therapeutics Inc. to Apply Company's Patented Technology in the Development of Premenstrual Syndrome Overeating Treatment
Date:1/6/2012

LONDON, Jan. 6, 2012 /PRNewswire/ -- Lightlake Therapeutics Inc. (OTCBB: LLTP - News) (the "Company" or "Lightlake"), an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today that it intends to develop a treatment for premenstrual syndrome (PMS) overeating using its patented technology involving opioid antagonists.

Current studies indicate that about 4 out of 10 women have symptoms of PMS, with many women suffering from PMS experiencing a sharp increase in craving for high-sweet and high-fat foods just before menstruation. This behavior is particularly upsetting among those women who are also overweight, which totals about 20 percent of all women of childbearing age. Endorphins, which are natural opioids, are released when sweets and high fat content foods are consumed, and the endorphins can eventually cause a form of food addiction that can be exacerbated by such disorders as PMS. Dr. David Sinclair of the National Institute for Health and Welfare in Finland and the Chief Scientific Officer of Lightlake previous work in the field of addiction has shown that endorphin-reinforced addictions are gradually weakened and removed with medicines called opioid antagonists.

Lightlake Therapeutics Inc. is currently conducting a randomized double blind placebo controlled trial in Helsinki of its patented treatment for extinguishing binge eating using the opioid antagonist, naloxone. In developing a similar treatment for PMS overeating, Lightlake plans to conduct multi-center clinical trials in the near future to address this global healthcare issue.

About Lightlake Therapeutics, Inc.

Lightlake Therapeutics Inc. is a developing biopharmaceutical company aiming to build a platform of biopharmaceutical solutions to common addictions and related disorders. Currently, the Company is focused on providing a safe, effective and simple treatment for patie
'/>"/>

SOURCE Lightlake Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Lightlake Therapeutics Inc Receives Ethical Approval to Begin Subject Selection for Future Phase II Clinical Trial for New Obesity Drug, in Helsinki, Finland
2. Pearl Therapeutics Announces Successful Completion of Phase 2b Safety and Efficacy Studies of COPD Combination, PT003
3. Orexigen Therapeutics to Present at the J.P. Morgan Healthcare Conference
4. Halo Therapeutics HT-100 Receives FDAs Orphan Designation for Duchenne Muscular Dystrophy
5. Echo Therapeutics Announces $3.6 Million Warrant Exercises
6. Echo Therapeutics to Present at Biotech Showcase 2012 in San Francisco
7. Orexigen® Therapeutics Completes Public Offering of Common Stock and Warrants to Purchase Common Stock
8. AuraSense Therapeutics Secures Series B Equity Investment
9. PTC Therapeutics Antibacterial Program Receives $5 Million Award from the Wellcome Trust
10. Arecor Forms Collaboration With Lilly to Develop Advanced Formulations of Protein Therapeutics
11. Cerevast Therapeutics Receives CE Mark for Clotbust ER™ Ultrasound Stroke Treatment Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... , June 18, 2013  Pro football player ... and professional family expert Jo Frost ... Mylan Specialty L.P., the fully integrated specialty pharmaceutical business ... raise awareness of this significant health problem. In recognition ... Food and Drug Administration (FDA) approval of EpiPen ® ...
(Date:6/17/2013)... , June 17, 2013  Hanger, Inc. (NYSE:  HGR) ... agreement that increases its senior secured facilities to an ... previously.  The new credit agreement includes a $200 million ... facility.  The previous credit agreement was comprised of a ... term loan.  Each new facility matures on June 17, ...
(Date:6/17/2013)... , June 17, 2013 The following is a ... Partnership at Drugfree.org :   Last Friday, ... it was halting the sale of prescription drug paraphernalia products. ... recognize that from time to time there may be individual ... customer. As a result of this misinterpretation we are electing ...
Breaking Medicine Technology:Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 2Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 3Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 4Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 5Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 6Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 7Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 8Hanger Enters New 5-Year Credit Agreement to Refinance Senior Secured Credit Facilities 2Hanger Enters New 5-Year Credit Agreement to Refinance Senior Secured Credit Facilities 3A Win for Families: Urban Outfitters Halts Prescription Drug Paraphernalia Product Sales 2
... CID s.r.l., a European company leader in interventional medicine, ... revolutionary drug eluting stent technology during The Drug Eluting ... Wednesday, September 22, 2010.  The lecture, entitled "Status of ... by Alexandre Abizaid, MD, PhD. Chief of Intervention at ...
... pleased to announce the addition of Kenneth ... to further the advancement of the group,s minimally invasive ... neurostimulators . Dr. Alo will serve as Director of ... graduated from Texas A&M University College of Medicine and ...
Cached Medicine Technology:CID to Update Interventional Cardiologists on Their Drug Eluting Stent Program at TCT 2010 2Kenneth Alo, M.D., Joins Ascendant Neuro as Director of Neuromodulation and Clinical Research 2Kenneth Alo, M.D., Joins Ascendant Neuro as Director of Neuromodulation and Clinical Research 3
(Date:6/18/2013)... Center clinical researchers have launched an innovative clinical ... the ability of a patient,s own stem cells ... arterial disease (PAD). , Led by Vik ... Hospitals Case Medical Center,s Harrington Heart & Vascular ... Reserve University School of Medicine, the clinical trial ...
(Date:6/18/2013)... 2013 The July 2013 issue of Marie ... Getting Beach Ready,” offers a list of home and doctor’s ... in a bathing suit this summer. The list includes treatment ... smoothing cellulite , and more. (go to goo.gl/aIe4J). , ... of Epione Beverly Hills, “though I would say some of ...
(Date:6/18/2013)... Atlanta (PRWEB) June 18, 2013 ... Cypress Care, ScripNet and Procura Management, today announced ... of chief sales officer. In this position, Leonardo ... support of the company’s strategic growth initiatives. , ... his leadership and expertise, Leonardo brings more than ...
(Date:6/18/2013)... 18, 2013 David Connett, DO, vice ... Medicine for the College of Osteopathic Medicine of the ... been elected president of the Osteopathic Medical Board ... Jr. appointed Connett, a 1984 alumnus of COMP, to ... elected Connett to the position during a conference call. ...
(Date:6/18/2013)... in the mammary gland appear to provide a crucial ... life, and the subsequent development of breast cancer, researchers ... 2013 issue of the journal Cancer Prevention Research ... associated with an increased risk of certain types of ... of social stress to cancer have been hard to ...
Breaking Medicine News(10 mins):Health News:UH Case Medical Center launches novel clinical trial using stem cells to prevent amputation 2Health News:Skin Care – Getting Your Body Beach Ready 2Health News:Healthcare Solutions Appoints Richard Leonardo to Chief Sales Officer 2Health News:Fat cells in breast may connect social stress to triple-negative breast cancer 2Health News:Fat cells in breast may connect social stress to triple-negative breast cancer 3Health News:Fat cells in breast may connect social stress to triple-negative breast cancer 4
... replacement therapy (HRT) may increase the risk of developing asthma ... of print in the journal Thorax . The ... quizzed about their use of HRT and development of asthma ... the women were taking part in the French E3N study, ...
... ... capture the authentic heartbeat of NY Jets Quarterback Mark Sanchez for a CBS Cares public ... is a favorite in broadcasting - this may be the biggest audience to hear the ... ...
... ... The inaugural meeting of The Global Leaders, a networking group of influential ... prestigious Yale Club in New York City on February 9th. There are ... companies, with more than $700 billion in annual revenue, $5 trillion in ...
... ... provider of trace level detection technologies based on the exploitation of Surface-Enhanced ... it has appointed David Burns as its new Chief Executive Officer. He ... diagnostic (IVD) products, with the aim to establish D3 Technologies as a ...
... to take steps to prevent illness , SATURDAY, Feb. 6 ... Vancouver can be champions of their health by following some ... the U.S. Centers for Disease Control and Prevention. , The ... by remembering to "Stop, Wash and Go:" , Stop. ...
... ... the St. Louis Jewish Community Center , ... St. Louis, MO (PRWEB) February 7, 2010 -- The Museum of ImaJewnation will ... located inside the St. Louis Jewish Community Center, Staenberg Family Complex Arts & Education Building ...
Cached Medicine News:Health News:Estrogen-only HRT may increase risk of asthma after menopause 2Health News:Superbowl Heartbeat from Thinklabs Electronic Stethoscope 2Health News:Global Leaders Hold Inaugural Meeting in New York City on February 9, 2010 2Health News:Ground Breaking Molecular Diagnostics Business Appoints New CEO 2Health News:Ground Breaking Molecular Diagnostics Business Appoints New CEO 3Health News:Spectators Need to Prepare for Olympic Games, Too 2
... catheters are designed using established technology ... following benefits:, ,Working with pH ... where the multi-use catheter is used ... contact to the skin.,NOTE: ,Medtronic pH ...
... Slimline single-use pH catheters are ... cross-contamination and allow greater patient comfort ... ,Medtronic pH measurement systems have been ... that allow an accurate room-temperature calibration. ...
The WaveMax is one of the most flexible stainless steel stents due to its unique wave design and has the lowest effective profile, accommodating a 6F sheath up to 7 mm....
... the world of online quality control ... control information and peer group statistics ... introduces a revolutionary internet based format ... Why rely on traditional quality control ...
Medicine Products: